| RESPONSABLE | CO-RESPONSABLE |
| Marc Le Borgne marc.le-borgne@univ-lyon1.fr | Thierry Lomberget thierry.lomberget@univ-lyon1.fr |
CHAMPS D’EXPERTISE
anticancer drugs, anti-infectious agents, kinase inhibitors, chemoresistance, efflux pump inhibitors, stability studies of APIs
ACTIVITES DE RECHERCHE / SERVICES
The B2MC laboratory develops research projects dedicated to anticancer drugs and molecular probes/compounds to fight chemoresistances. We could design, synthesize and optimize diverse scaffolds such as heterocycles, dipeptides and steroids. For example, to design protein kinase CK2 inhibitors, diverse strategies are developed to get either ATP-competitive, or allosteric or protein-protein interaction inhibitors. A second research project is also developed: the design of efflux pump modulators. By using structural diversity of scaffolds, we have targeted ABC proteins such as Pg-p, BCRP and MRP-1.
COMPETENCES / MOYENS TECHNIQUES
Inside Drug Discovery and Drug Design programs, we develop ligand-based drug design, chemical synthesis, synthetic methodology, heterocyclic synthesis, SAR analysis, structural optimization (hit and lead), chiral separations by HPLC. Our Team has a small molecule library containing fragments, functionalized heterocycles, steroidal scaffolds and dipeptides.
OU NOUS TROUVER ?
8, avenue Rockefeller, 69373 Lyon Cedex 08